Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice tight range...time to gap-up
Fud. it's satrean, at least he was an intellectual....
The shorts are hard at work today. The destruction of companies must be some sort of weird fetish for these purveyors of low moral standards.
Basically..it's traders that have borrowed(short) stock without taking ownership(long)and then not being forced(squeezed) into buying it within a given timeframe
This science will enable people to basically google their own heritage!!!
E-trade has yet to place this NEWS on their site.
Bagger..arguing with Frud or Frog is like using a two headed coin...no matter which side it lands on you lose
Point being 252,000,000 shares @.02 does'nt add up to squat when your paying people to conduct research work, buying companies, equipment and materials.
OK. Now next question. How many scientists would work for free, developing a science that, for all intents and purposes, delivers at blinding speed the DNA sequences that determine the origin of a man (or woman), the efficacy of drugs and place that potential on your lap??
How many of those "additional" shares were used to purchase other companies? How many were sold directly into the market to fund ongoing operations?
That's the question
Dilution?? I would challenge this speculation by asking that proof be offered that the company has been selling additional shares of stock. the number of shares traded on any given day does not prove "dilution".
Has anyone called the transfer agent and asked if the company has issued or sold stock into the market?? If so, what would that agent be able or willing to tell you regarding "dilution"?
Excellent article in Newsweek regarding DNA and Ancestry. Seems that DNAG is getting more and more attractive.
E-trade still has not posted this exceptionally important news??!!
That would explain his sudden disapearence
I wonder why the news isn't appearing on e-trades site???
Jeves..DNAG moves it's shares to the frankfurter exchange...Hot Dog!!!
This has to be one of lowest volume days yet..hmmm whats up with that??
jever, which move are you refering to?? the move to a new exchange or a move to the downside???
slippery slope...EOM
Save..Suck it up or shove off
ROFLMAO...precisely
Jeves..time for a new crystal ball
Excellent read in the January issue.
Genomes for All
Next-generation technologies that make reading DNA fast, cheap and widely accessible are coming in less than a decade. Their potential to revolutionize research and bring about the era of truly personalized medicine means the time to start preparing is now
By George M. Church
When the World Wide Web launched in 1993, it seemed to catch on and spread overnight, unlike most new technologies, which typically take at least a decade to move from first "proof of concept" to broad acceptance. But the Web did not really emerge in a single year. It built on infrastructure, including the construction of the Internet between 1965 and 1993, as well as a sudden recognition that resources, such as personal computers, had passed a critical threshold.
Vision and market forces also push the development and spread of new technologies. The space program, for example, started with a government vision, and only much later did military and civilian uses for satellites propel the industry to commercial viability. Looking forward to the next technological revolution, which may be in biotechnology, one can begin to imagine what markets, visions, discoveries and inventions may shape its outcome and what critical thresholds in infrastructure and resources will make it possible.......continued at Scientific American Digital
jeves.I'm glad to hear you used your personal influence and power to drive NITE to it's knees. Now if you could just use you all knowing abilities to release the sp from it's current performance we will all be very greatful
jeves..have you been watching sanford & son reruns again??
renewed interest
NHGRI Pledges $420M to Support Genome Sequencing Centers; Adoption of New Tech Encouraged to Reduce Costs
By a GenomeWeb staff reporter
NEW YORK, Dec. 29 (GenomeWeb News) - The National Human Genome Research Institute has allocated $130 million for fiscal year 2006 to renew its large-scale sequencing program, according to a request for applications published on the National Institutes of Health website.
NHGRI allocated up to $420 million in total costs, to be awarded over four years, the solicitation said. The institute expects to make three to five awards, for a maximum period of four years. The earliest anticipated start date is Nov. 1, 2006.
NHGRI is encouraging the adoption of next-generation sequencing technologies that it expects to reduce the cost of large-scale sequencing projects by five-fold or more over the next four years. The institute "recognizes that the renewal of its genomic sequencing program comes at a time when significant advance(s) in genomic sequencing technology can be anticipated," the RFA said. "In renewing the sequencing program, NHGRI intends to provide adequate funding to encourage sequencing centers to explore adoption of the new technologies. Therefore, the applicant should discuss the new sequencing technologies and should describe any plans s/he has for implementation of one or more of them."
The RFA said that improvements in sequencing technology "have allowed the NHGRI to decrease the amount of funding for the program in each of the last four years, from a high of over $180 million to its current FY 2006 level of $133 million, while more than tripling output over that time."
NHGRI said in the RFA that centers funded under the program will continue a number of comparative genomic sequencing projects that are generating data for annotating the human genome, "while an increasing fraction of the sequencing capacity will be directed to medical sequencing, which is expected to result in the identification of genomic changes implicated in heritable disease and the elucidation of the genetic changes associated with cancer."
The program will also focus on sequencing eukaryotic pathogens and "vectors of human disease," NHGRI said.
Letters of intent are due Jan. 11, and applications must be received by April 11, 2006.
Hopeful.. Let's see $35,000,000 in financing, aquired 3 companies for STOCK. Apparently, there must be either a huge conspiracy to defraud (lie)or something else afoot that would not only support their value but the value of these poor innocent co-conspirators (Kenna, Trace, Biofronera, Dutchess)who in your, frogs & Dr. frauds opinion are worthless liars.
Merry Christmas
DNA based medicines on the way....
CytoGenix and Aldevron Announce Positive Results of synDNA(TM) Hepatitis Vaccine Study
December 19, 2005 17:04:01 (ET)
HOUSTON & FARGO, N.D., Dec 19, 2005 (BUSINESS WIRE) -- CytoGenix, Inc. (CYGX, Trade) and Aldevron, LLC announced positive results of a pilot study using CytoGenix synDNA(TM) as the active ingredient in a Hepatitis B vaccine, demonstrating that it is highly effective in generating an immune response.
DNA vaccines are comprised of genes that confer immunologic protection by producing antigens without the need to expose the body to pathogenic organisms. For this study, CytoGenix scientists prepared a synthetic DNA vaccine derived from a plasmid provided by Aldevron that produces a Hepatitis B viral surface antigen. Aldevron's scientists tested CytoGenix synDNA(TM) vaccine's activity in a rabbit model using Aldevron's proprietary Genetic Immunization and Antibody (GIA(TM)) technology.
Aldevron scientists compared levels of gene-specific serum immunoglobulin produced by the synDNA(TM) vaccine to its traditional plasmid DNA vaccine. The synDNA(TM) vaccine generated immunoglobulin levels in the test animals up to five times greater than a comparable plasmid DNA vaccine produced by bacterial fermentation.
Frank Vazquez, CytoGenix, Inc.'s Executive Vice President and COO, commented, "These results are very important because they confirm the effectiveness of synDNA(TM) that we have seen in other animal studies of DNA vaccines. It is clear that our synDNA(TM) process produces bio-active DNA. This latest result is a major step forward in our efforts to accelerate CytoGenix' Rapid Response Vaccine Development Program against H5N1 avian flu, smallpox and other infectious disease targets."
Michael Chambers, Aldevron President and CEO, stated, "Aldevron has supported the DNA vaccine field for the past seven years by providing quality DNA, antibody and protein products as well as by sponsoring scientific forums and maintaining the DNAvaccine.com web site. The synDNA(TM) process is potentially a big step forward in the DNA vaccine and gene medicine fields. We look forward to expanding Aldevron-CytoGenix scientific and business collaboration."
About CytoGenix: CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology.
About Aldevron: With facilities in the United States and Europe, Aldevron offers products and services to DNA vaccine and gene therapy scientists. These include contract bio-manufacturing, genetic immunization and antibody production, and a complete line of gene therapy plasmids. More information can be found at http://www.aldevron.com.
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission
Big News next week...just thought I would beat jever0000 to his usual drivel
jeves...does today qualify as tomorrow????
Actually, it must still be there because I don't think the cranialanalectomy has been perfected yet..given his usual Friday prediction
No jever000 in almost 2 days...maybe he joined ilwill
Is this NOT your post??? Idi_t
Is English difficult for you too?
Read it again....slowly.
DNAG is not an accredited crime lab! ASCLD like Orchid, but remember DNAG promised us they were going to get it, just another broken promise!
The subject is ASCLD accreditation and DNAG's promise that they were getting it
Oh by the way frog if your so down on DNAG, sell your shares and go play in someone elses pond!!
froggy..we supply the test kits to forensic labs that actually DO the testing. Those labs ARE accredited.
This is the type of study that would be well suited to DNAG's testing. If Pfizer conducts this as an independant study with the Cleveland Clinic, I would think that other big pharm will follow suit.
Testing the efficacy these drugs is something that DNAG is targeting.
December 14, 2005
Pfizer to Finance $100 Million Safety Study of Celebrex
By STEPHANIE SAUL
Pfizer, the pharmaceutical giant, is betting big on the safety of its cox-2 painkiller, Celebrex.
The company has agreed to finance a study with an estimated cost of more than $100 million to examine the safety of Celebrex in arthritis patients prone to heart attack and stroke.
To lead the study, Pfizer has turned to an early critic of the cox-2 painkillers, Dr. Steven E. Nissen, a cardiologist at the Cleveland Clinic.
Dr. Nissen announced yesterday that the clinic's cardiovascular research center would coordinate the study of about 20,000 patients. He called it the first large-scale trial to compare the safety of a cox-2 painkiller with older nonsteroidal anti-inflammatory drugs in high-risk patients.
"This could show that celecoxib is the best drug or the worst drug," said Dr. Nissen, using the generic name for Celebrex. He said the study was a big gamble for Pfizer.
The trial could provide answers for millions of patients who have various forms of arthritis. Along with their doctors, many of those patients have struggled to weigh the risks and benefits of painkillers since September 2004, when Merck voluntarily withdrew its cox-2 drug, Vioxx, after a study showed that it increased the risk of heart attacks and strokes.
Since then, a Pfizer cox-2 drug, Bextra, has also been withdrawn.
"We're certainly very pleased that the Cleveland Clinic is heading the study and it is about to get under way, because clearly this is an important question and a very important patient population that the study is going to look at," said a Pfizer spokeswoman, Mariann Caprino.
Ms. Caprino said that it would be premature to discuss the potential costs of the study, but Dr. Nissen said that studies of this size cost at least $100 million.
Worldwide sales of Celebrex, the only remaining cox-2 drug marketed in the United States, have declined 45 percent since last year, but the drug still had revenue of $1.26 billion in the first nine months of this year, according to company figures.
The study could increase Celebrex sales by raising consumer confidence in the drug. Other companies that are developing new-generation cox-2's, including Merck, have expressed hope that the class will regain some of its luster after the risks and benefits are sorted through.
Pfizer first said in October 2004, just weeks after the cox-2 controversy arose, that it planned to undertake a long-term study to prove Celebrex's safety.
The idea was raised again at a meeting of a Food and Drug Administration panel in February that reviewed painkiller safety. Dr. Robert Temple, the director of medical programs for the F.D.A., and several panel members suggested a study to compare a cox-2 with other nonsteroidal anti-inflammatory drugs.
"It may be that at the end of this, one or the other drug will be superior," said Dr. Alastair Wood of Vanderbilt University, a professor of medicine and pharmacology who headed the panel and now recommends the painkiller naproxen instead of Celebrex. "That's exactly what we need to know."
Dr. Nissen, who served on the F.D.A. panel, said he began talks with Pfizer last summer to coordinate the trial, which will involve study sites around the world. The study will not include countries of the European Union, where authorities recommend against use of Celebrex by high-risk heart patients.
Patients in the study will have some form of arthritis along with histories including a previous heart attack, stroke, angina, coronary bypass surgery or stent procedure, Dr. Nissen said. Others will have diabetes, a known risk factor for cardiovascular disease.
"All the other trials that I'm aware of are really in quite low-risk patients, and so they just aren't comparable," he said.
Enrollment will begin next year and patients will be followed for about two years. One-third of the patients will be given Celebrex; one-third Motrin, or ibuprofen; and one-third will receive Aleve or Naprosyn, both brand names for naproxen.
The study will end when about 700 of the patients have died or had a heart attack or stroke, the number expected in such a high-risk group even without painkiller treatment.
Hopefull..your postings have obviously been carefully selected portions of the reports issued. There is a great deal of promise in what is actually being written.
Also, if you were on the leading edge of introducing a new ground breaking science, would you put out specific information on what exactly you were doing??
It would be kind of like playing poker with all of your cards showing..don't you think??
unusually low volume
Thanks Virgil...hopefully we will get the meat and potatos(or potatoes for you Gore fans) from the archive
Missed the webcast..what happened?